About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 531640, 6 pages
Research Article

Carbohydrate 19.9 Antigen Serum Levels in Liver Disease

1Department of Medical and Pediatric Sciences, Hepatology Unit, University of Catania, 95123 Catania, Italy
2International Ph.D. Program in Neuropharmacology, University of Catania, 95123 Catania, Italy
3Research Center “The Great Senescence”, University of Catania, 95125 Catania, Italy
4Department of Biomedical Sciences, University of Sassari, 07100 Sassari, Italy

Received 23 June 2013; Revised 10 September 2013; Accepted 12 September 2013

Academic Editor: Aleksandra Nikolic

Copyright © 2013 Gaetano Bertino et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Motoo, Y. Satomura, I. Mouri et al., “Serum levels of pancreatitis-associated protein in digestive diseases with special reference to gastrointestinal cancers,” Digestive Diseases and Sciences, vol. 44, no. 6, pp. 1142–1147, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. M. F. Plemenos, C. Dimas, A. Kotsios, K. Gennatas, and A. Kondi-Pafiti, “Prognostic significance of the immunohistochemical localization and serological detection of CA19-9 tumor antigen in colon carcinoma,” Journal of B.U.ON, vol. 9, no. 1, pp. 73–76, 2004. View at Scopus
  3. K. Markocka-Maczka, “Ca 19-9 antigen in differentiation of pancreatic inflammatory and neoplastic tumors,” Wiadomosci Lekarskie, vol. 56, no. 11-12, pp. 537–540, 2003. View at Scopus
  4. M. Ducreux, V. Boige, and D. Malka, “CA 19-9 and pancreatic carcinoma, a revival?” Onkologie, vol. 30, no. 1-2, pp. 12–13, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Nouts, P. Lévy, H. Voitot, and P. Bernades, “Diagnostic value of Ca 19-9 antigen in patients with chronic pancreatitis or pancreatic adenocarcinoma: effects of complications,” Gastroentérologie Clinique et Biologique, vol. 22, no. 2, pp. 152–159, 1998. View at Scopus
  6. N. Tanaka, S. Okada, H. Ueno, T. Okusaka, and M. Ikeda, “The usefulness of serial changes in serum CA19-9 levels in the diagnosis of pancreatic cancer,” Pancreas, vol. 20, no. 4, pp. 378–381, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Nowak, D. Jakubowska, A. Wiczkowski et al., “Carbohydrate antigens CA 19-9, CA 242, CA 50 in liver diseases,” Wiadomości Lekarskie, vol. 51, no. 11-12, pp. 484–491, 1998. View at Scopus
  8. Y. Kitagawa, M. Iwai, A. Muramatsu et al., “Immunohistochemical localization of CEA, CA19-9 and DU-PAN-2 in hepatitis C virus-infected liver tissues,” Histopathology, vol. 40, no. 5, pp. 472–479, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. O. Uygur-Bayramiçli, R. Debak, E. Orbay et al., “Type 2 diabetes mellitus and CA 19-9 levels,” World Journal of Gastroenterology, vol. 13, no. 40, pp. 5357–5359, 2007. View at Scopus
  10. É. Szekanecz, Z. Śandor, P. Antal-Szalmás et al., “Increased production of the soluble tumor-associated antigens CA19-9, CA125, and CA15-3 in rheumatoid arthritis: potential adhesion molecules in synovial inflammation?” Annals of the New York Academy of Sciences, vol. 1108, pp. 359–371, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Safadi, M. Ligumsky, E. Goldin, Y. Ilan, Y. S. Haviv, and S. Nusair, “Increased serum CA 19-9 antibodies in Sjogren's syndrome,” Postgraduate Medical Journal, vol. 74, no. 875, pp. 543–544, 1998. View at Scopus
  12. E. Giannini, P. Borro, F. Botta et al., “Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis,” International Journal of Biological Markers, vol. 15, no. 3, pp. 226–230, 2000. View at Scopus
  13. K. H. Park, J. S. Kim, J. H. Lee et al., “Significances of serum level and immunohistochemical stain of CA19-9 in simple hepatic cysts and intrahepatic biliary cystic neoplasms,” The Korean Journal of Gastroenterology, vol. 47, no. 1, pp. 52–58, 2006. View at Scopus
  14. X. Vandemergel, F. Vandergheynst, and G. Decaux, “Very high elevation of CA19-9 level in a patient with steatosis,” Acta Gastro-Enterologica Belgica, vol. 68, no. 3, pp. 380–381, 2005. View at Scopus
  15. M. Montalto, L. Santoro, M. Vastola et al., “Normalisation of high CA 19-9 values in autoimmune hepatitis after steroidal treatment,” International Journal of Immunopathology and Pharmacology, vol. 18, no. 3, pp. 603–607, 2005. View at Scopus
  16. E. De Goede and S. H. Yap, “An exceptional high concentration of serum CA 19.9 in a patient with alcoholic liver disease,” Gut, vol. 41, no. 4, pp. 579–580, 1997. View at Scopus
  17. S. Maestranzi, R. Przemioslo, H. Mitchell, and R. A. Sherwood, “The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA,” Annals of Clinical Biochemistry, vol. 35, no. 1, pp. 99–103, 1998. View at Scopus
  18. P. Simmonds, A. Alberti, H. J. Alter et al., “A proposed system for the nomenclature of hepatitis C viral genotypes,” Hepatology, vol. 19, no. 5, pp. 1321–1324, 1994. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Bedossa and T. Poynard, “An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group,” Hepatology, vol. 24, no. 2, pp. 289–293, 1996. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Kodama, H. Satoh, H. Ishikawa, and M. Ohtsuka, “Serum levels of CA19-9 in patients with nonmalignant respiratory diseases,” Journal of Clinical Laboratory Analysis, vol. 21, no. 2, pp. 103–106, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. W. Steinberg, “The clinical utility of the CA 19-9 tumor-associated antigen,” American Journal of Gastroenterology, vol. 85, no. 4, pp. 350–355, 1990. View at Scopus
  22. A. Andriulli, T. Gindro, P. Piantino, et al., “Prospective evaluation of the diagnostic efficacy of CA 19-9 assay as a marker for gastrointestinal cancers,” Digestion, vol. 33, no. 1, pp. 26–33, 1986. View at Scopus
  23. G. Bertino, A. Ardiri, M. Malaguarnera, G. Malaguarnera, N. Bertino, and G. S. Calvagno, “Hepatocellualar carcinoma serum markers,” Seminars in Oncology, vol. 39, pp. 410–433, 2012.
  24. M. Schöniger-Hekele and C. Müller, “The combined elevation of tumor markers CA 19-9 and CA 125 in liver disease patients is highly specific for severe liver fibrosis,” Digestive Diseases and Sciences, vol. 51, no. 2, pp. 338–345, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Malaguarnera, I. Paladina, M. Giordano, M. Malaguarnera, G. Bertino, and M. Berretta, “Serum markers of intrahepatic cholangiocarcinoma,” Disease Markers, vol. 34, pp. 219–228, 2013.
  26. G. Malaguarnera, M. Giordano, I. Paladina, et al., “Markers of bile duct tumors,” World Journal of Gastrointestinal Oncology, vol. 3, pp. 49–59, 2011.
  27. G. Malaguarnera, M. Giordano, I. Paladina, M. Berretta, A. Cappellani, and M. Malaguarnera, “Serum markers of hepatocellular carcinoma,” Digestive Diseases and Sciences, vol. 55, no. 10, pp. 2744–2755, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Giannini, D. Risso, F. Botta et al., “Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease,” Archives of Internal Medicine, vol. 163, no. 2, pp. 218–224, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. C.-T. Wai, J. K. Greenson, R. J. Fontana et al., “A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C,” Hepatology, vol. 38, no. 2, pp. 518–526, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. N. V. Chrysanthos, G. V. Papatheodoridis, S. Savvas et al., “Aspartate aminotransferase to platelet ratio index for fibrosis evaluation in chronic viral hepatitis,” European Journal of Gastroenterology and Hepatology, vol. 18, no. 4, pp. 389–396, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. F. Imbert-Bismut, V. Ratziu, L. Pieroni, F. Charlotte, Y. Benhamou, and T. Poynard, “Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study,” The Lancet, vol. 357, no. 9262, pp. 1069–1075, 2001. View at Publisher · View at Google Scholar · View at Scopus
  32. K. A. Gebo, H. F. Herlong, M. S. Torbenson et al., “Role of liver biopsy in management of chronic hepatitis C: a systematic review,” Hepatology, vol. 36, no. 5 I, pp. S161–S172, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. R. Bataller, Y.-H. Paik, J. N. Lindquist, J. J. Lemasters, and D. A. Brenner, “Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells,” Gastroenterology, vol. 126, no. 2, pp. 529–540, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. G. Bertino, A. M. Ardiri, P. Boemi et al., “Meaning of elevated CA 19-9 serum levels in chronic hepatitis and HCV-related cirrhosis,” Minerva Gastroenterologica e Dietologica, vol. 53, no. 4, pp. 305–309, 2007. View at Scopus
  35. T. Stroffolini, A. Spadaro, V. Di Marco, et al., “Current practice of chronic hepatitis B treatment in Southern Italy,” European Journal of Internal Medicine, vol. 23, pp. 124–127, 2012.
  36. G. Bertino, A. Ardiri, P. M. Boemi, et al., “Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis,” European Journal of Clinical Pharmacology, vol. 66, pp. 1055–1063, 2010.